News
Public · Published
How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks — Barrons.com
At a major cancer medicine conference, Merck presented trial results for sac-TMT, a drug it licensed from China's Sichuan-Kelun Pharmaceutical. Nearly 40% of drugs in clinical trials, and about half of cancer drugs, originated in China, Barrons.com reported.
Published:
Updated:
What happened
At a major cancer medicine conference, Merck presented trial results for sac-TMT, a drug it licensed from China's Sichuan-Kelun Pharmaceutical. Nearly 40% of drugs in clinical trials, and about half of cancer drugs, originated in China, Barrons.com reported.
Confirmed
Global impact / market context
Chinese-invented drugs are moving toward Western approval and sales, so U.S.-listed drugmakers that license them could gain new revenue as older products lose patent protection. Investors gain exposure to this innovation wave through American shares rather than only Hong Kong listings.
Analyst inference
Licensing deals shift much of the commercial upside to U.S. companies with regulatory and sales reach, as Merck's deal with Kelun and Summit's license of Akeso's drug show. Pfizer's CEO expects Chinese firms to be major competitors by 2030.
Analyst inference
What to watch
- Watch Merck's sac-TMT trial progress and approval steps, because Merck hopes revenue from this licensed Chinese drug will offset expiring Keytruda patents. Confirmed
- Track Summit Therapeutics' ivonescimab data, licensed from Akeso, as it aims to compete with Keytruda in cancer treatment. Confirmed
- Watch licensing deal terms and U.S. regulatory decisions, which determine how much profit from Chinese drug inventions flows to American shareholders. Analyst inference
Evidence
- Original source link unavailable